In the present study, we assessed the therapeutic potential of inhibiting the MAPK/ERK pathway with MEK1/2i to reprogram CD8+ T-lymphocytes for the use in Lewis lung carcinoma cell therapy in vitro and in vivo. This evidence concerns the gene CD8A and Carcinoma, Lewis Lung.